Volume | 568,912 |
|
|||||
News | - | ||||||
Day High | 119.91 | Low High |
|||||
Day Low | 117.06 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sarepta Therapeutics Inc New | SRPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
117.50 | 117.06 | 119.91 | 117.12 | 116.96 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,497 | 568,912 | $ 118.51 | $ 67,422,927 | - | 55.25 - 159.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:11:24 | 6 | $ 116.99 | USD |
Sarepta Therapeutics (SRPT) Options Flow Summary
Sarepta Therapeutics Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
10.99B | 93.86M | - | 1.24B | -535.98M | -5.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sarepta Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 117.60 | 119.91 | 114.37 | 116.84 | 630,019 | -0.48 | -0.41% |
1 Month | 129.83 | 131.16 | 114.37 | 123.63 | 623,616 | -12.71 | -9.79% |
3 Months | 120.50 | 143.00 | 114.37 | 126.29 | 810,472 | -3.38 | -2.80% |
6 Months | 111.00 | 143.00 | 55.25 | 99.97 | 1,329,891 | 6.12 | 5.51% |
1 Year | 127.17 | 159.89 | 55.25 | 110.25 | 1,257,591 | -10.05 | -7.90% |
3 Years | 71.27 | 159.89 | 55.25 | 101.98 | 1,107,461 | 45.85 | 64.33% |
5 Years | 113.98 | 181.83 | 55.25 | 106.72 | 1,145,889 | 3.14 | 2.75% |
Sarepta Therapeutics Description
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. |